H.C. Wainwright Keeps Their Buy Rating on Harpoon Therapeutics (HARP)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Harpoon Therapeutics (HARPResearch Report), with a price target of $7.00. The company’s shares closed yesterday at $0.81.

According to TipRanks, Ramakanth is an analyst with an average return of -14.5% and a 28.97% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as ImmunoGen, Alaunos Therapeutics, and MiMedx Group.

Harpoon Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $5.10, which is a 526.84% upside from current levels. In a report released on November 14, SVB Securities also reiterated a Buy rating on the stock with a $4.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $8.20 and a one-year low of $0.70. Currently, Harpoon Therapeutics has an average volume of 160.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. It offers Tri-specific T cell Activating Construct (TriTACs) that focuses on the treatment of solid tumors and hematologic malignancies. The company founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

Read More on HARP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More